Ann: Half Yearly Report and Accounts, page-34

keeping what under wraps? This isnt the Illuminati.
Poor management and lack of proof of concept is the reason this stock is 13c

It will go back upto 50c if we are lucky post SVR (If its positive)
We will have cured Hep C, but not be pursuing it (to finally have some revenue) then we have to start from scratch to prove the tech again in Hep B.

Only positive that could come out of it is that big pharma were waiting for that and give us a deal, but pre-SVR on Hep b means the deal will more than likely be pretty shabby IMO.

$50-$100 share price, if ever is 10 years away now mate....